Express News | Silence Therapeutics PLC : Morgan Stanley Raises Target Price to $49.00 From $45.00

ReutersJun 28 07:26 ET

Express News | Silence Therapeutics PLC: Divesiran Was Well Tolerated

ReutersJun 27 07:31 ET

Express News | Silence Therapeutics: Divesiran Eliminated Need for Phlebotomy in All Well-Controlled Patients Following Infrequent Dosing

ReutersJun 27 07:31 ET

Express News | Silence Therapeutics Announces Positive Results From Ongoing Sanreco Phase 1 Study of Divesiran in Polycythemia Vera Patients

ReutersJun 27 07:30 ET

Express News | Silence Therapeutics: Study Demonstrated Highly Significant and Sustained Reductions in LP(a) to Week 48

ReutersJun 20 07:31 ET

Express News | Silence Therapeutics Announces Positive Topline 48-Week Data From Phase 2 Study of Zerlasiran in Patients With Elevated Lipoprotein(a)

ReutersJun 20 07:30 ET